Bullfrog AI Sends Letter to Stockholders, Highlighting Achievements and Strategic Direction

On December 27, 2024, Bullfrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) issued a letter to its stockholders outlining the company’s progress and strategic direction. The letter, signed by CEO Vin Singh, expressed appreciation for the steadfast support of stockholders and highlighted key achievements throughout the year.

Looking back on 2024, the letter emphasized significant advancements made by Bullfrog AI. The company’s proprietary bfLEAP™ platform was notably enhanced by integrating generative and causal AI technologies with graph analytics licensed from Johns Hopkins University’s Applied Physics Laboratory. This development enables Bullfrog AI to generate explainable and reproducible AI results, supporting various applications in drug development, including drug target discovery and biomarker prediction.

A strategic collaboration with the Lieber Institute for Brain Development (LIBD) led to groundbreaking insights into neuropsychiatric disorders, such as schizophrenia and bipolar disorder. These insights, facilitated by Bullfrog AI’s AI platform, are expected to result in significant commercial agreements in 2025.

Another highlight mentioned in the letter was the progress made with the BF-114 research, which demonstrated promising potential in treating obesity and related liver diseases. The company also received additional patent protections for BF-223, an oncology drug candidate, further enhancing its value and potential for collaborations.

The letter emphasized the strengthening of Bullfrog AI’s intellectual property portfolio, the expansion of its scientific and leadership teams, and the maintenance of a robust cash position through successful equity offerings totaling $8.83 million in 2024.

Moving forward into 2025, Bullfrog AI aims to focus on driving value through innovation, strategic collaborations, and the commercialization of AI-driven solutions. The company plans to leverage its AI capabilities to capitalize on the increasing demand for AI-enabled drug development and expand its market reach.

In conclusion, the letter thanked stockholders for their ongoing support and invited them to join Bullfrog AI on its journey to revolutionize drug development in the upcoming year. The company remains optimistic about the future, believing that 2025 holds transformative opportunities for continued growth and success. Further details about Bullfrog AI, its technology, and collaborations can be found on the company’s website.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Bullfrog AI’s 8K filing here.

Bullfrog AI Company Profile

Bullfrog AI Holdings, Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.